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Abstract HTLV-I generally integrates at least one full-length 
copy in adult T-cell leukemia (ATL) cells. A group of patients 
without full-length provirus have a unique conserved truncation 
of the provirus which retains env-pX-3"LTR. Tumor cells of a 
patient from this group were genetically analyzed. Analysis of the 
5' and 3' cellular flanking region adjacent o the provirus suggest 
that the defective provirus was integrated immediately down- 
stream of a promoter of an unknown cellular gene. The activity 
of the promoter was weak but was responsive to Tax-like HTLV- 
I LTR. The provirus may have utilized it as a substitute for the 
5'LTR and thus 3'LTR may have become an alternative promoter 
for the cellular gene, which may give similar viral-cellular inter- 
actions to that of general cases with full-length proviruses. Sur- 
prisingiy, the 3' cellular flanking region which is thought to be 
controlled originally by the promoter is constitutively expressed 
specifically in an HTLV-I producing ATL cell line HUTIO2G,  
in which the corresponding region is not modified by provirus. The 
detection of this HTLV-I-induced transcript provides a probe to 
find an HTLV-I inducible unknown cellular gene that may be 
related to the pathogenesis of ATL. 
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1. Introduction 
Evidence suggests that human T-cell leukemia virus type I 
(HTLV-I) must be the etiological agent of adult T-cell leukemia 
(ATL) [1,2]. These observations are supported by recent molec- 
ular and cellular biological studies that revealed the involve- 
ment of the viral trans-activator, Tax protein of HTLV-I, in its 
oncogenic potential. Tax protein can immortalize human T- 
lymphocyte [3] and transform Rat-1 cells in vitro [4], and is 
required for the maintenance of the malignant phenotype of 
Tax-transformed Rat-1 cells [5]. The oncogenic properties of 
Tax are thought o be based on interactions of Tax with cellular 
factors, such as the NF-kB family [6], Etsl [7] and p67 sRF [6,8], 
which eventually cause the transactivation of various host 
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genes including IL-2 [9], IL-2 receptor a chain [10,11], GM-CSF  
[12,13], MHC class I [14], c-fos oncogene [15,16] and so on 
[17,18,19]. In spite of this evidence, however, no one has suc- 
ceeded to transform normal T-cells to malignancy via direct 
infection with HTLV-I particles so far. Therefore the patho- 
genic pathway from virus entry to ATL may include numerous 
complex interactions between cellular and viral factors, espe- 
cially Tax. 
While analyzing many cases of ATL, we found a group that 
contains a defective HTLV-I provirus (without any full-length 
provirus) composed of env-pX-LTR [20]. One of them was 
genetically analyzed and extraordinarily long direct repeats 
were identified at the integration sites as previously reported 
[21]. We have further characterized this isolate and obtained 
data suggesting the env-pX-LTR provirus may be able to cause 
typical ATL through a novel cis-interaction with an HTLV-I- 
induced cellular gene to simulate a full-length HTLV-I provirus 
in the cell. 
2. Materials and methods 
2.1. Molecular clones 
The molecular clone pOHS13 which contains the defective nv-pX- 
LTR provirus of HTLV-I with cellular flanking sequence at both ends 
was obtained as previously described from an ATL patient R [11,20,21]. 
The clinical findings of patient R are summarized inTable 1. The other 
clone named pBS(5 + 3)A includes the fragment which corresponds to 
the sequence around the integration point derived from the genomic 
DNA of MOLT-4. As previously characterized, there was no major 
rearrangement among various human cell lines including HUT102G 
in the subcloned area [21]. Nucleotide sequences was determined by an 
estublished chain-termination sequencing method. 
2.2. Cells 
COS7 cells (a monkey kidney cell line) were maintained inDulbecco's 
modified Eagle minimum essential medium (D-MEM) supplemented 
with 10% fetal calf serum (FCS). An HTLV-I producing human T-cell 
line HUT102G [1], HTLV-I-free human lymphoid cell lines including 
MOLT-4 and Jurkat were grown in RPMI 1640 medium supplemented 
with 10% FCS. 
2.3. Plasmids for CAT assay 
Every plasmid for CAT assay possesses a part of the region around 
the 5' viral-cellular junction of pOHS 13 upstream of bacterial chloram- 
phenicol acetyl-transferase (CAT) gene. The plasmid pF1CAT was 
constructed by inserting a PstI-HindlII fragment of pOHS13 into the 
HindlII site of pSVOCAT [22]. Similarly, an EcoRI-HinclI fragment 
was subcloned into pSVOCAT to be pF2CAT. In this construct, a
HindlII site was conserved on the HincII-end of the insert. The PstI- 
BamHI fragment of pF2CAT which contains the common region of 
pF1CAT and pF2CAT from pOHS13 fused to CAT gene, SV40 t- 
splicer and polyadenylation signal was subcloned at the corresponding 
sites of pUc119. The resultant plasmid was designated as pUcF3CAT. 
To construct a deletion mutant pUcF4CAT, the polymerase chain- 
reaction (PCR) product from pUcF3CAT was substituted for the PstI- 
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HindlII fragment of pUcF3CAT. Primers were synthesized by an auto- 
mated DNA synthesizer. Cloning diagram is shown in Fig. 2A. 
2.4. DNA transfection and CAT assay 
Cesium chloride-purified plasmids were introduced into COS7 cells 
by either calcium-phosphate co-precipitation method or DEAE-dex- 
tran-mediated method following established protocols as previously 
described [23,24]. Twenty-four hours prior to transfection, 2 x 105 cells 
were seeded in a 6 cm tissue-culture dish. For calcium-phosphate trans- 
fections, 5/lg of pF1CAT, pF2CAT, pUcF3CAT or pUcF4CAT and 
10 mg of pKCR40M (a Tax expressor) or pKCRH2 (the parental 
plasmid of pKCR40M without exogenous cDNA) were subjected to a 
single experiment. For DEAE-dextran transfections, we used 10/.tg of 
pF1CAT, pF2CAT, pUcF3CAT or pUcF4CAT. Seventy-two hours 
after transfection, cells were harvested and their lysate was prepared by 
3 cycles of freeze-thawing followed by centrifugation toremove debris. 
The CAT activity was estimated by a standard protocol as previously 
shown [22,25]. 
2.5. RNA preparation and RNase protection analysis 
Total RNA extracts were made from HUT102G, MOLT-4 and 
Jurkat cells by an acid guanidinium thiocyanate (GTC)/phenol/chloro- 
phorm (AGPC) method as previously described [26]. Riboprobes were 
transcribed in vitro by bacteriophage T3 RNA polymerase using 
BamHI or SpeI-digested pBS(5 + 3)A as a template (for probe strand) 
or by bacteriophage T7 RNA polymerase using HindIII-digest- 
ed pBS(5+3)A as a template (for sense strand) in the presence of 
[0~-32P]UTR The transcription reaction was performed following the 
manufacturer's protocol with a commercial kit (Stratagene, CA). Dia- 
grams of the resultant probes are shown in Fig. 4A. Ten micrograms 
of each total RNA was hybridized with 5 x 10 s cpm of 32p-labeled probe 
in a hybridization buffer containing 80% formamide at 45°C overnight 
and digested by RNase A and RNase T1 under the condition described 
previously [27]. After digestion protected probe fragments were ana- 
lyzed under denaturing conditions (Fig. 4B). 
2.6. GenBank/EMBLIDDBJ accession umbers 
Sequence data appeared in this study are partially available under 
accession umber X75259 and fully available under accession umber 
X84992 for gene ARP in Fig. 1 and X84993 for gene ART in Fig. 3. 
3. Results 
3.1. Tax-responsive promoter activity in the 5"-flanking sequence 
Since the defective provirus was lacking its 5' LTR, we sus- 
pected the existence of a functional substitute of the 5' LTR in 
the 5' cellular flanking region. Nucleotide sequence analysis of 
this region revealed typical eukaryotic TATA-box unit and its 
homologue. In addition, several enhancer-like sequences 
[28,29] and an element homologous to the NF-xB binding con- 
sensus [30] were also identified (Fig. 1), which suggest hat it 
may contain a functional promoter. Subfragments derived from 
the 5'-flanking region were isolated and subcloned into pSVO- 
CAT to determine their activity as promoters, but we could 
detect no CAT activity in COS7 cells transfected with these 
plasmids alone. However, when co-transfected with a Tax-ex- 
pression plasmid, 3 out of 4 plasmids displayed etectable CAT 
activity (Fig. 2). As the three plasmids (pF1CAT, pF2CAT and 
pUcF3CAT) share the common PstI-HincII subfragment, he 
Tax-responsive weak promoter activity comes from this region. 
This fragment includes the putative TATA-box and the en- 
hancer-like lements, however, pUcF4CAT has them as well, 
but has shown no detectable promoter activity even in the 
presence of Tax. All the CAT assays were repeated at least three 
times and gave similar results (data not shown). The nucleotide 
sequence was subjected to the homology-search of GenBank 
and EMBL. No significant homologues were found in reported 
sequences. 
3.2. Nucleotide sequence of the Y-flanking corresponding region 
in MOLT-4 cells 
Since the putative TATA box was located near the integra- 
tion site, the putative gene which is thought o have been driven 
by the promoter should exist beyond the defective provirus in 
EcoRI Psfl HindlII 
pOHS13 ~ .......... L J .  / 
PstI 
EcoRI 
env I pX LTR 
CTGCAGCTCCT CGGACCTGAA GGTGGATCGA CCATATTCAA AGGAGGGAGC TGGCCAGAAG CTGGGCTCTG 
-310 NF-KB-I ike 
ATAGTTGTTA ATTTCGTCCT TCTAATAACC TATTCATCGT TCCCACCCAG G A ~ ~ G A A T T T C  
-240 enhancer- l ike 
AGAGCACCAG CAGCAAAGGG TAGGGCCAGA AGGTGCTGGA ~ TAACAGGCGG TATTATTATC 
-170 enhancer - l ike  
AGGATTCAGC AGTGCAATTG ATTCCTGCTC ATGTGTCCCA CGAAATATAG CACTGTT~~ATC 
-I00 
TTAGAATGAG AGACTGGGGA TTTTGGTCTC AGTTCCTACC TTACCATACC ACTGAATTAC CTCAGATAAA 
-30 ~_q_9~.~lar ~0~ V i ra l~ 
TTCCTTCTCT CAGCTTCTAA~ATAAA~TAA AATAATGCTC TATCCATAGC CCTATGGGAC AATCAACCAC 
40 HincII t JUNCTION 
CTGAATGTGT TAACCAACTG CCACAAAACC CGATGGCAGC GTTCACCACT CCCCCCGACT CCAGCCGATC 
Ii0 HindIII 
CCAGAGACAC ATTCCCTCAG CAATAAACAA ACCCATTG~ATTAT~TCAAGCTT 
Fig. 1. Structure of the de~ctive HTLV-I provirus from patient R and the nucleotide sequence around the 5' integration site. Small boxes in the scheme 
represent 5' and 3' cellular flanking regions. Within these areas, the novel direct repeats reported previously are shown in solid black and marked 
with arrows over the boxes. The repeated region is underlined in the nucleotide sequence. TATA box-like elements are boxed. Shaded regions indicate 
NF-xB-like binding site and enhancer core-like sequences. Several recognition sites ~r  restriction endonucleases are shown. 
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Fig. 2. Tax-responsive promoter activity in the 5'-flanking region. (A) Construction ofthe 5'-flanking-CAT plasmids. The regions ubcloned upstream 
of bacterial CAT gene are shown as hatched boxes. Sequence numbers displayed here correspond to those in Fig. 1. Schematic representation f 
the structure around the 5' viral-cellular junction is shown below for comparison. The NF-xB-like binding site and TATA box-like sequences are 
also included. (B) CAT activities from COS7 cells transfected with these plasmids. Lane 1 = co-transfected with pKCR40M (a Tax expresser); lane 
2 = co-transfected with pKCRH2 (parental vector of pKCR40M). F1, F2, F3 and F4 denote pF1CAT, pF2CAT, pUcF3CAT and pUcF4CAT, 
respectively. 
the case of patient R. Therefore, the 3'-flanking region of 
pOHS 13 may contain a fragment of the putative gene. First, we 
determined the nucleotide sequence of the 3'-flanking corre- 
sponding region of the MOLT-4 genome; however, there were 
no significant coding frames long enough to encode a protein 
in the sequenced area (Fig. 3B). In our previous study, we 
Table 1 
Clinical observations in patient R. The values of physical and hematol- 
ogic findings of 35 cases [32] are summerized 
Reported cases Patient R 
Age (Y) 27-73 51 
(median = 51) 
Symptoms Enlarged 86% + 
lymphonode 
Hepatomegary 77% + 
Splenomegary 51% 
Skin lesions 49% ++ 
Peripheral W.B.C. (/cm 2) 9700-499000 198000 
Survival perod ~6M 68% 6M 
6M-12M 26% 6M 
12M ~ 6% 6M 
reported that in the case of patient R, both 5'-3'-flanking se- 
quences contain 99 bp-long direct repeats at the viral integra- 
tion sites, whereas the 5'-3'-fused correspondent in MOLT-4 
genome contains a single sequence. We found no difference 
between patient R's 3' flanking sequence and its corresponding 
sequence of MOLT-4 except he repeats. Also the electromobil- 
ity of PCR-derived 5'-3'-fused correspondent from HUT102G 
was exactly the same as MOLT-4 [21]. Fig. 3A summarizes 
these previous findings. The nucleotide sequence has shown a 
unique SpeI site at the middle area of the 3'-flanking corre- 
sponding region. No significant homologues were found by 
searching the data bases EMBL and GenBank. 
3.3. Detection of specific transcripts within the 3"-flank&g 
corresponding region in HUT1 02G 
Utilizing the internal SpeI site and vector-derived BamHI 
site, we could prepare two riboprobes for detection of tran- 
scripts using pBS(5+3)A in which the 5'-3'-fused corre- 
spondent from MOLT-4 is subcloned. RNase protection analy- 
sis with these radiolabeled probes has shown several distinct 
protected fragments when hybridized with the total RNA from 
34 
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Fig. 3. (A) Structural comparison of cellular flanking regions and their 
correspondents. The subcloned area of pOHS 13 is the EcoRI fragment 
of patient R's genome. Closed boxes represents he subcloned flanking 
regions and the correspondents. Hatched areas denote sequences with- 
out repeat. Solid areas represent the sequences repeated inR's genome. 
Primers (AIP, NP) used for isolating and subcloning the corresponding 
part of MOLT-4 genomic DNA to pBS(5 + 3)A are also illustrated. The 
large arrow below pBS(5 + 3)A indicates the sequenced region displayed 
in panel B. (B) Nucleotide sequence of the Y-flanking corresponding 
region of MOLT-4. Most of the repeated sequence appeared in Fig. 1 
is omitted and its 3' end is involved here and underlined. The internal 
SpeI recognition site and the binding site of a primer are indicated. 
TAAAATAAAG GGATGGTTTC CATAATCTCT TGCGATGGCT TGAATCTCTT 
CCACTCTCAC CTTGTTAGTA CATTTCCACT TATTTCCGTT ACTTGT'I"f~C 
TGATCTTTAA GCCTTGTCGC CTGTTTTATT TAAGTTTTAA TGCAATCGCC 
S~el  
CTGT'PTGACA CTAGT'rGACC CCTCATC'I'~GG GTGTCACATG TGACTCTGTG 
AATTTTAACT CTTGTCCCTT GAATGAGTGG AGGTAAGAGT TCAGCTAAGT 
GACCTCTGCT CCCCTAGCCC CAGGGAACTT CGGGTAAGGG ATTCAGAGAA 
GGC,PGATGTC ATq~CAqICAC C. 
NP  
probe covers only a part of the 3'-flanking region of approxi- 
mately 160 bases. As shown in Fig. 4B, there was no difference 
in size of the protected probe RNAs between these two probes. 
This finding proves that the HUTIO2G-specific transcripts 
originate in the corresponding region of the Y-flanking region. 
Although we attempted to determine the transcription i itia- 
tion site(s) of these transcripts by primer-extension a alysis, it 
has not been successful, due to no information about which 
part of the region covered by the shorter probe would be tran- 
scribed. Accordingly it is likely that we have not prepared an 
appropriate primer. 
4. Discussion 
HUT 102G (Fig. 4), whereas no such signal occurred in HTLV- 
1-free T-cell lines, Jurkat and MOLT-4. Similar experiments 
under a radiolabeled sense-strand RNA from pBS(5 + 3)A re- 
vealed no specific band in every cell line tested (data not 
shown). Thus, this region is actively expressed specifically in 
HUT102G sharing the same sense-strand with the defective 
HTLV-I in R's genome. The longer probe contains most area 
of the 5' flanking as well as the T-flanking region. The shorter 
Our study has pointed out two interesting aspects of ATL. 
One is the detection of an unknown transcript expressed specif- 
ically in an ATL cell line that possesses full-length HTLV-I 
provirus and actively produces virus particles. The induction 
of the expression should be undertaken in trans possibly by 
viral Tax protein, since there is no proviral integration around 
the transcribed region, which was previously shown by PCR 
[21] and genomic Southern blot hybridization (data not shown), 
A 
MOLT-4  
pBS(5+3)A 
Riboprobes 
EcoRI AlP SpeI EcoRI  
........................ ! ........... ~. . .  ~ . . . . . . . . . . . . . . . .  
NP i 
I 
II 
Banffll SpeI .~Iind HI 
T7 : T3 
i 
i 
B 
234 
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1 2 3 4 5  1 2 3 4  
310 ,,-- 
~t = 
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194 
118 
118 
Probe I Probe II 
Fig. 4. (A) Riboprobes obtained from pBS(5 + 3)A. T3 and T7 represent specific promoters for in vitro transcription with bacteriophage T3 and T7 
RNA polymerase, respectively. BamHI and HindlII recognition sites originate in the multiple cloning site of the parental plasmid, while SpeI is the 
internal one shown in Fig. 3B. Other information is displayed in Fig. 3. (B) Detection of specific transcripts in HUT102G. Left panel: RNase 
protection analysis with radiolabeled probe I. Lane 1 = DNA size marker; lane 2 = HUT102G; lane 3 = MOLT-4; lane 4 = Jurkat; lane 5 = tRNA. 
Right panel: RNase protection analysis with radiolabeled probe II. Lane 1 = DNA size marker; lane 2 = undigested probe; lane 3 = HUT 102G; lane 
4 = MOLT-4. Sizes of DNA markers are shown in numbers of bases with arrowheads. The undigested probe looks longer than 160 bases due to 
the difference of electromobility between RNA and DNA and addition of an extra vector-derived sequence. 
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Fig. 5. Schematic omparison of the proviral host interactions of a 
general ATL case versus patient R. 'TRP' is an abbreviation of Tax- 
responsive promoter. Wide boxes with 'TRP' followed by skinny long 
boxes denote Tax-responsive g nes in general. Stippled one represents 
the gene analyzed in this study. 
and a Tax-responsive promoter upstream of the transcribed 
area is strongly suggested. Although we have not strictly spec- 
ified which element was responsible for the Tax dependent 
promoter activity, we found a 118 bp area that is crucial for it. 
In this case, something more than the NF-kB binding site-like 
element was required for its Tax-responsiveness. It is likely that 
unknown cellular factor(s) may mediate this regulation like 
several cellular genes, which should be clarified in the near 
future. Then interestingly, in the ATL case we analyzed, the 
same region was modified by a defective proviral integration 
at a point between the putative promoter and the transcribed 
area, then eventually the disrupted gene could revive under the 
control of 3'LTR. In the area we sequenced, we could not 
specify any supposed protein encoded. However, it is likely for 
detected RNA fragments to be connected with other exon(s) 
downstream of the sequenced area by splicing. In fact, we 
detected at least three different fragments in the same area, 
suggesting the involvement of alternative splicing. Although we 
have not yet succeeded to isolate the entire gene at present, we 
are currently trying to obtain a better probe by exon-trapping 
method in order to pick up the whole cDNA. 
The other interesting point is the novel mode of the integra- 
tion of patient R's provirus. The role of this kind of defective 
provirus in ATL has been controversial, since it lacks the 
5'LTR for transcription of viral gene products. It might look 
like a fossil without ranscriptional machinery. However, it had 
been reported that Tax is essential for maintenance of malig- 
nant phenotypes in transformed cells in vitro [5]. If so, even 
such a defective provirus may have expressed Tax to maintain 
malignancy in vivo. 
In the case of patient R, the defective provirus was the only 
HTLV-1 provirus in the host genome and could simulate the 
intact provirus by integrating in a novel manner (Fig. 5). By 
integrating between the promoter and the transcribed region of 
a certain gene which may be related to the progression and 
maintenance ofATL, the defective provirus may have regained 
the regulatory machinery and could provide biological effects 
on host cells similar to that of a full-length provirus integrated 
35 
anywhere in the host cell genome. Unfortunately, since neither 
RNA nor cell extract from this patient is in our hands, we are 
not able to verify the hypothesis further. However, the defective 
provirus could act like a full-length HTLV-I provirus without 
gag/pol genes that may be dispensable for ATL-leukomogene- 
sis. It is noteworthy that this patient R displayed typical symp- 
toms and findings of ATL throughout his illness (Table 1), 
despite having the defective provirus. 
Recently it has been reported that the pol-env region of 
HTLV-I provirus contains a weak Tax-independent internal 
promoter which may act as an early promoter for Tax-expres- 
sion [31]. It is a most interesting discovery that gave insights in 
the complex regulation of gene expression of HTLV-I. How- 
ever, the promoter does not necessarily guarantee the onco- 
genic potential of such an env-pX-LTR provirus. If the pro- 
moter is strong enough to cause and maintain the malignant 
phenotype of ATL cells, the clinical feature of patient R should 
have been far different from typical ATL. On the contrary, if 
the promoter is too weak to cause it, an additional factor to 
trigger ATL should be required. In the case of patient R, the 
additional factor could be the novel cis interaction with the host 
genome. In this point of view, it is also interesting to analyze 
the clinical features of ATL cases that have only one env-pX- 
LTR defective provirus in relation to the mode of cis interac- 
tion of the provirus and the host genome; for the clinical fea- 
tures of these cases may be strongly influenced by such addi- 
tional factors provided in cis in the absence of 5'LTR. Finally, 
they may give information that help us to explain the long 
pathway from HTLV-I infection to ATL. 
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